Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROSTAMIP: 99mTc-MIP-1404 SPECT/CT for Primary Prostate Cancer Staging
2024-516083-28-00Phase 3Authorised
- Sponsor
- Turku University Hospital
- Start
- Dec 2024
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of trofolastat in prostate cancer (PCa) (2 arms), sponsored by Turku University Hospital. Planned start Dec 2024; status: authorised.
02
Drugs
trofolastat
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2024-516083-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516083-28-00.